ABOUT EVENT
について
关于
Tentang
The World Companion Diagnostics & Liquid Biopsy Summit APAC was your premier industry meeting, bringing together leading experts from biopharma - including Amgen, AstraZeneca, Johnson & Johnson and CStone Pharmaceuticals, academia such as Fudan University and National University of Singapore, and world-class service providers to discuss the latest advancements in biomarker development, liquid biopsy testing, and companion diagnostics. This comprehensive two-day forum offered a unique platform for fostering meaningful collaborations and business partnerships.
Attendees gained valuable insight into the industry's biggest challenges and opportunities; including regulatory updates, reimbursement routes, and innovative strategies for accelerating patient access to precision therapies. This was your chance to hear the latest breakthroughs in biomarker discovery and liquid biopsy technologies with greater sensitivity, enabling earlier and more effective disease diagnosis. By uniting key stakeholders across the region, this meeting aimed to drive innovation and development of personalized medicine solutions in the Asia-Pacific market.
What You Missed
見逃した内容
你错过的内容
Apa yang Anda Terlepas
Navigating rapidly evolving regulatory guidelines across the region to streamline approvals and enable greater patient access to precision therapeutics with insights from Bristol Myers Squibb, Kyowa Kirin & Johnson & Johnson
Overcoming barriers to market access with robust precision medicine strategies from clinical trials to companion diagnostic launch and tactical partnership selection to fast-track global development and commercialization of drugs/diagnostics with insights from Bristol Myers Squibb, Daiichi Sankyo & Omico
Gaining insight into how more sensitive and specific liquid biopsies are enabling earlier disease diagnosis and more effective response monitoring using ctDNA analysis as an early endpoint for optimized treatment regimes with insights from Johnson & Johnson, Fudan University & Takeda
Learning how novel technologies including digital pathology and machine learning can optimise patient selection with enhanced prescreening for clinical trials to improve patient experience and outcomes with insights from Sanofi
Discovering how to more accurately stratify patients with robust clinical biomarker development to make impactful decisions during treatment for improved therapeutic outcomes with insights from Harbour BioMed & OBI Pharma